Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10806)
All Articles published online
|
Publishing Process of This Article
|
Sep 28, 2015 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015; 21(36): 10314-10326 [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i36/10314.htm |
| Number | Citing Articles |
| 1 |
Menglong Zhang, Weiguo Lai, Jian Zhang, Bijuan Hu, Liyin Huang, Cunkun Chu, Gerhard Schmalz. Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma. Disease Markers 2022; 2022: 1 doi: 10.1155/2022/6957580
|
| 2 |
M. S. Korovin, A. N. Fomenko. Application of nanodimensional particles and aluminum hydroxide nanostructures for cancer diagnosis and therapy. 2017; 1882: 020036 doi: 10.1063/1.5001615
|
| 3 |
Mohammad Telfah, Mohammed Al-Jumayli, Anwaar Saeed. Liver Cancer. 2018; doi: 10.5772/intechopen.79872
|
| 4 |
Yuan Nie, Mei-chun Jiang, Cong Liu, Qi Liu, Xuan Zhu. CXCL5 Has Potential to Be a Marker for Hepatocellular Carcinoma Prognosis and Was Correlating With Immune Infiltrates. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.637023
|
| 5 |
Encheng Yang, Xiao Li, Ningyi Jin. The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment. Cancer Cell International 2016; 16(1) doi: 10.1186/s12935-016-0351-0
|
| 6 |
Jing Cao, Fan-Hua Kong, Xi Liu, Xiao-Bo Wang. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World Journal of Gastroenterology 2019; 25(27): 3649-3663 doi: 10.3748/wjg.v25.i27.3649
|
| 7 |
Peng Qin, Mengyu Zhang, Xue Liu, Ziming Dong, Fazlullah Khan. Immunogenomic Landscape Analysis of Prognostic Immune-Related Genes in Hepatocellular Carcinoma. Journal of Healthcare Engineering 2021; 2021: 1 doi: 10.1155/2021/3761858
|
| 8 |
Qi Meng, Xiuyun Duan, Qingchao Yang, Dewen Xue, Zihao Liu, Yuanyuan Li, Qingyan Jin, Fang Guo, Shijie Jia, Zhaofeng Wang, Wenjiang Yan, Xu Chang, Peng Sun. SLAMF6/Ly108 promotes the development of hepatocellular carcinoma via facilitating macrophage M2 polarization. Oncology Letters 2022; 23(3) doi: 10.3892/ol.2022.13203
|
| 9 |
Bongseo Choi, Hyunjun Choi, Heegon Kim, Ashley Choi, Soon-Woo Kwon, Samdeep K. Mouli, Robert J. Lewandowski, Dong-Hyun Kim. Z-domain protein nano-bio interfaced MRI visible anti-program death ligand-1 nanoconjugates for enhanced local immune checkpoint inhibitor immunotherapy. Nano Today 2022; 45: 101552 doi: 10.1016/j.nantod.2022.101552
|
| 10 |
R. Diaz-Beveridge, G. Bruixola, D. Lorente, J. Caballero, E. Rodrigo, Á. Segura, D. Akhoundova, A. Giménez, J. Aparicio. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clinical and Translational Oncology 2018; 20(3): 322 doi: 10.1007/s12094-017-1720-4
|
| 11 |
Malek Kreidieh, Youssef H. Zeidan, Ali Shamseddine. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. Journal of Oncology 2019; 2019: 1 doi: 10.1155/2019/4304817
|
| 12 |
Yu Akazawa, Toshihiro Suzuki, Toshiaki Yoshikawa, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-Analysis 2019; 7(3): 80-95 doi: 10.13105/wjma.v7.i3.80
|
| 13 |
Jian Zhang, Huizhong Li, Dazhi Gao, Baofu Zhang, Maojin Zheng, Mingyin Lun, Mengxue Wei, Rui Duan, Maomao Guo, Jiajun Hua, Qian Liu, Jin Bai, Hui Liu, Junnian Zheng, Hong Yao. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biology & Therapy 2018; 19(6): 475 doi: 10.1080/15384047.2018.1433501
|
| 14 |
Zhixuan Ren, Jiakang Zhang, Dayong Zheng, Yue Luo, Zhenghui Song, Fengsheng Chen, Aimin Li, Xinhui Liu. Identification of Prognosis-Related Oxidative Stress Model with Immunosuppression in HCC. Biomedicines 2023; 11(3): 695 doi: 10.3390/biomedicines11030695
|
| 15 |
Yingjun Xie, Yien Xiang, Jiyao Sheng, Dan Zhang, Xiaoxiao Yao, Yongsheng Yang, Xuewen Zhang. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. Journal of Immunology Research 2018; 2018: 1 doi: 10.1155/2018/8740976
|
| 16 |
B. Gottstein, P. Soboslay, E. Ortona, J. Wang, A. Siracusano, D.Α. Vuitton. Echinococcus and Echinococcosis, Part B. Advances in Parasitology 2017; 96: 1 doi: 10.1016/bs.apar.2016.09.005
|
| 17 |
Eric A. Mellon, Gilbert Murimwa, Sarah E. Hoffe. Radiation Therapy for Liver Tumors. 2017; : 269 doi: 10.1007/978-3-319-54531-8_20
|
| 18 |
Nazanin Momeni Roudsari, Naser-Aldin Lashgari, Saeideh Momtaz, Amir Hossein Abdolghaffari. Cancer Immunology. 2020; : 241 doi: 10.1007/978-3-030-57949-4_9
|
| 19 |
Adhiraj Dasgupta, Dhritiman Dey, Dipanjan Ghosh, Tapan Kumar Lai, Nattamai Bhuvanesh, Sandip Dolui, Ravichandiran Velayutham, Krishnendu Acharya. Astrakurkurone, a sesquiterpenoid from wild edible mushroom, targets liver cancer cells by modulating Bcl‐2 family proteins. IUBMB Life 2019; 71(7): 992 doi: 10.1002/iub.2047
|
| 20 |
Dong-Hyun Kim. Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma. Journal of Liver Cancer 2022; 22(2): 93 doi: 10.17998/jlc.2022.03.28
|
| 21 |
Rajagopal Aravalli, Clifford Steer. Immune-Mediated Therapies for Liver Cancer. Genes 2017; 8(2): 76 doi: 10.3390/genes8020076
|
| 22 |
Malek Kreidieh, Deborah Mukherji, Sally Temraz, Ali Shamseddine. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. BioMed Research International 2020; 2020: 1 doi: 10.1155/2020/9037217
|
| 23 |
Juan Shen, Xiao Tu, Yuanyuan Li. Mathematical Modeling Reveals Mechanisms of Cancer-Immune Interactions Underlying Hepatocellular Carcinoma Development. Mathematics 2023; 11(20): 4261 doi: 10.3390/math11204261
|
| 24 |
Smita Kapoor, Yogendra S. Padwad. Colon Cancer Diagnosis and Therapy. 2021; : 309 doi: 10.1007/978-3-030-63369-1_15
|
| 25 |
Jiang-Zheng Zeng, Yu Liu, Fen Huang, Zhi-Hui He, Huamao Sun, Yan-Da Lu, Jun-Hua Lei, Rong-Cheng Luo. Glypican-3-specific cytotoxic T lymphocytes induced by human leucocyte antigen-A*0201-restricted peptide effectively kill hepatocellular carcinoma cells in vitro. Asian Pacific Journal of Tropical Medicine 2017; 10(11): 1084 doi: 10.1016/j.apjtm.2017.10.013
|
| 26 |
Magnus Rizell, Malin Sternby Eilard, Mats Andersson, Bengt Andersson, Alex Karlsson-Parra, Peter Suenaert. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00019
|
| 27 |
Huaqiang Bi, Kai Feng, Xiaofei Wang, Ping Zheng, Chengming Qu, Kuansheng Ma. Transcriptomic and metabolomic analysis of peri-tumoral hepatic tissue in hepatocellular carcinoma: unveiling the molecular landscape of immune checkpoint therapy resistance. Frontiers in Pharmacology 2024; 14 doi: 10.3389/fphar.2023.1304996
|
| 28 |
Qing Zhang, Xiang‐Fei Yuan, Yang Lu, Zhen‐Zhen Li, Shi‐Qi Bao, Xiao‐Long Zhang, Yuan‐Yuan Yang, Dong‐Mei Fan, Yi‐Zhi Zhang, Chen‐Xuan Wu, Hong‐Xing Guo, Yan‐Jun Zhang, Zhou Ye, Dong‐Sheng Xiong. Surface expression of anti‐CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A‐engineered human umbilical cord mesenchymal stem cells. International Journal of Cancer 2017; 141(7): 1445 doi: 10.1002/ijc.30846
|
| 29 |
Keyu Li, Yaliang Lan, Jiabei Wang, Lianxin Liu. Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles. Tumor Biology 2017; 39(3): 101042831769222 doi: 10.1177/1010428317692229
|